Cannabis Rescheduled to Schedule III — What It Means for Your Tax Position

On April 23, 2026, the U.S. Department of Justice and the Drug Enforcement Administration issued a landmark final order moving certain marijuana products from Schedule I to Schedule III of the Controlled Substances Act (CSA). The reclassification applies immediately to two categories: FDA-approved drug products containing marijuana, and marijuana subject to a qualifying state-issued medical marijuana license.

This is the most significant shift in federal drug policy in over 50 years — and for cannabis operators, their investors, and their financial advisors, the tax implications deserve careful and immediate attention.

What Changed — and What Didn't

The Final Order does not broadly legalize cannabis. It does not affect recreational or adult-use marijuana, which remains a Schedule I controlled substance. Synthetically derived THC is also unaffected. The order is targeted and conditional: only state-licensed medical marijuana operators and holders of FDA-approved marijuana products are rescheduled.

For those who do qualify, however, the consequences are substantial.

Under Schedule I status, Section 280E of the Internal Revenue Code prohibited cannabis businesses from deducting ordinary and necessary business expenses. This meant cannabis companies were effectively taxed on gross profit rather than net income — a punishing tax structure that often resulted in effective tax rates exceeding 70%. With the move to Schedule III, state-licensed medical marijuana operators may no longer be subject to 280E beginning April 22, 2026.

The 280E Relief: What It Means in Practice

For any cannabis business that has been operating under 280E, the potential relief is significant:

Prospective deductions restored. Going forward, qualifying operators can deduct ordinary and necessary business expenses — salaries, rent, marketing, professional fees, and more — reducing taxable income to something approximating economic reality.

Amended returns worth exploring. The IRS has not yet issued formal guidance, but operators should evaluate whether filing amended returns for open tax years (generally 2022–2025) is appropriate. The Treasury Department has been encouraged by the order to consider "retrospective relief," though no formal transitional rules have been issued as of this writing.

Entity structure matters. For cannabis businesses operating as partnerships or S corporations, the timing of when 280E relief takes effect may depend on IRS guidance around tax year elections. C corporations may have more flexibility to capture deductions in a shorter period. Entities should consult with tax counsel before making structural changes.

Key Action Items for Cannabis Operators and Their CFOs

1. Segregate medical and recreational cost data now.

If your operation includes both state-licensed medical and adult-use recreational activity, you need systems in place to separately track costs attributable to each. Only the medical operations qualify for the rescheduling relief. Mixed operations without clean cost segregation will face significant challenges in claiming deductions and defending them on audit.

2. Evaluate amended return exposure.

Work with your tax advisor to identify the open tax years and calculate the potential benefit of filing protective claims or amended returns. The benefit may be meaningful — but the IRS has not confirmed retroactive relief, so proceed carefully and document your analysis.

3. Update your financial models.

If your business has been projecting cash taxes under 280E assumptions, your models are now out of date. Reforecast your effective tax rate, cash taxes, and net income under post-rescheduling assumptions. This has direct implications for valuations, lender covenants, and investor reporting.

4. Monitor the June 29, 2026 DEA hearing.

A broader administrative hearing begins on June 29, 2026 to evaluate whether all marijuana — including recreational — should be rescheduled to Schedule III. The outcome of that proceeding will shape the regulatory and tax landscape for the entire industry. Cannabis companies and their advisors should track this closely.

5. Watch for IRS transitional guidance.

The Final Order expressly states it does not constitute a determination of federal tax liability. Treasury and the IRS must still provide formal guidance on how Section 280E applies in the context of this rescheduling, including effective dates, transitional rules, and treatment of mixed-use operations. That guidance may arrive as a Notice, Revenue Procedure, or regulatory update — any of which could materially affect tax planning.

What This Means for Investors

For investors in cannabis companies — whether venture, private equity, or family office — the rescheduling has meaningful implications for portfolio valuation and due diligence:

- Improved margins and cash flow. The removal of 280E from medical operations directly improves after-tax cash flows, which should be reflected in updated financial projections and valuations.

- Cleaner diligence. With a clearer federal framework for medical operators, due diligence on cannabis investments becomes more tractable. Tax exposure under 280E has been a persistent uncertainty in cannabis M&A — that uncertainty is now partially resolved for qualifying businesses.

- Recreational operations remain in limbo. The rescheduling does not resolve the federal-state conflict for adult-use cannabis. Investors with exposure to recreational operations should continue to monitor the June 2026 hearing and any subsequent Congressional action.

Our Perspective

The April 2026 rescheduling is a genuine milestone — one that the cannabis industry has anticipated for years. But it is also a carefully bounded action, and the details matter enormously. Operators who move too quickly without IRS guidance risk overstating deductions. Operators who wait too long may leave meaningful tax savings on the table.

At Agility Financial Partners, we work with companies navigating complex tax and regulatory environments. If your business has cannabis exposure — whether as an operator, an investor, or a lender — we are happy to discuss how these developments apply to your specific situation.

This article is for informational purposes only and does not constitute legal or tax advice. Consult qualified counsel before making tax filing decisions based on the April 2026 rescheduling order.

*Sources: U.S. DOJ/DEA Final Order, April 23, 2026; Foley & Lardner LLP; Foley Hoag LLP; Duane Morris LLP; Congressional Research Service LSB11105.*